Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.

International journal of molecular sciences - 19 Jul 2021

Giordano Guido, Parcesepe Pietro, Bruno Giuseppina, Piscazzi Annamaria, Lizzi Vincenzo, Remo Andrea, Pancione Massimo, D'Andrea Mario Rosario, De Santis Elena, Coppola Luigi, Pietrafesa Michele, Fersini Alberto, Ambrosi Antonio, Landriscina Matteo

Abstract excerpt

Target-oriented agents improve metastatic colorectal cancer (mCRC) survival in combination with chemotherapy. However, the majority of patients experience disease progression after first-line treatment and are eligible for second-line approaches. In such a context, antiangiogenic and anti-Epidermal Growth Factor Receptor (EGFR) agents as well as immune checkpoint inhibitors have been approved as second-line...

Topics

Join the communities discussing this publication.

Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Pharmacological
Clinical Trials, Phase III as Topic
Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Precision Medicine

Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 34299337
DOI: 10.3390/ijms22147717
PMCID: PMC8307359

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.PMID 34299337Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

Molecular-Biology-Driven Treatment for Metastatic Colorectal CancerSemantic proximity Read ↗

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.Semantic proximity Read ↗

The past, present, and future treatment of BRAFV600-mutant metastatic colorectal cancer: A comprehensive review.Semantic proximity Read ↗

Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2.Semantic proximity Read ↗

Molecular Targets for the Treatment of Metastatic Colorectal CancerSemantic proximity Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer.Semantic proximity Read ↗

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

A Critical Review of Second-Generation Anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Semantic proximity Read ↗

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.